Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Issue 2 (February 2016)

• Record Type: Journal Article
• Authors: Pontali, Emanuele; Sotgiu, Giovanni; D'Ambrosio, Lia; Centis, Rosella; Migliori, Giovanni Battista
• Is Part Of: European respiratory journal. Volume 47:Issue 2(2016)
• Page Start: 394
• Page End: 402
• Publication Date: 2016-02
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01891-2015
• Languages: English
• ISSNs: 0903-1936

Abstract

The importance of adequately managing multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) cases for TB control and elimination are underlined in the new World Health Organization (WHO) "End TB Strategy" [1, 2] as part of pillar one (integrated, patient-centred care and prevention; element 2: treatment of all people with TB including drug-resistant TB, and patient support) and in the recently published "Framework towards TB elimination in low incidence countries" in its priority action 5 (optimise the prevention and care of drug-resistant TB) and the related background documents [3–5]. Furthermore, both in the End TB Strategy (pillar 3: intensified research and innovation) and in the Framework towards TB elimination in low incidence countries (priority action 7: invest in research and new tools) the need for new anti-TB drugs is strongly emphasised [1, 3, 6]. The reasons why new anti-TB drugs are needed are rather obvious if you look closely at the dimensions of the MDR-TB epidemic and the treatment successes achieved so far. Systematic review of the available scientific evidence on the role of bedaquiline in new effective M/XDR-TB regimens http://ow.ly/V68ZF